Technical feasibility of newborn screening for spinal muscular atrophy by next-generation DNA sequencing.

Autor:	Shum BOV; Preventive Health Division, Genepath, Sydney, NSW, Australia.; EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of NSW, Sydney, NSW, Australia., Henner I; Preventive Health Division, Genepath, Sydney, NSW, Australia., Cairns A; Neurosciences Department, Queensland Children's Hospital, Brisbane, QLD, Australia., Pretorius C; Department of Chemical Pathology, Pathology Queensland, Queensland Health, Brisbane, QLD, Australia., Wilgen U; Department of Chemical Pathology, Pathology Queensland, Queensland Health, Brisbane, QLD, Australia., Barahona P; Preventive Health Division, Genepath, Sydney, NSW, Australia., Ungerer JPJ; Department of Chemical Pathology, Pathology Queensland, Queensland Health, Brisbane, QLD, Australia.; Faculty of Health and Behavioural Sciences, University of QLD, Brisbane, QLD, Australia., Bennett G; Preventive Health Division, Genepath, Sydney, NSW, Australia.
Jazyk:	angličtina
Zdroj:	Frontiers in genetics [Front Genet] 2023 Jan 12; Vol. 14, pp. 1095600. Date of Electronic Publication: 2023 Jan 12 (Print Publication: 2023).
DOI:	10.3389/fgene.2023.1095600
Abstrakt:	Newborn screening (NBS) assays for spinal muscular atrophy (SMA) typically use a polymerase chain reaction (PCR) based assay to identify individuals with homozygous deletion in exon 7 of the SMN1 gene. Due to high DNA sequence homology between SMN1 and SMN2 , it has previously been difficult to accurately bioinformatically map short reads from next-generation DNA sequencing (NGS) to SMN1 , resulting in low analytical performance and preventing NGS being used for SMA screening. Advances in bioinformatics have allowed NGS to be used in diagnostic settings, but to date these assays have not reached the scale required for high volume population newborn screening and have not been performed on the dried blood spot samples that NBS programs currently use. Here we integrate an NGS assay using hybridisation-based capture with a customised bioinformatics algorithm and purpose designed high throughput reporting software into an existing NBS program to achieve a laboratory workflow for population SMA screening. We tested the NGS assay on over 2500 newborns born over 2 weeks in a NBS program in a technical feasibility study and show high sensitivity and specificity. Our results suggest NGS may be an alternate method for SMA screening by NBS programs, providing a multiplex testing platform on which potentially hundreds of inherited conditions could be simultaneously tested. Competing Interests: BS, IH, PB, and GB are shareholders of Genepath which developed the assay used in the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Shum, Henner, Cairns, Pretorius, Wilgen, Barahona, Ungerer and Bennett.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu